Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022
Open Access
- 30 March 2023
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (13), 2200494
- https://doi.org/10.2807/1560-7917.es.2023.28.13.2200494
Abstract
Background Understanding the epidemiology of reinfections is crucial for SARS-CoV-2 control over a long period. Aim To evaluate the risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time after first infection. Methods We conducted a cohort study including all residents in the Reggio Emilia province on 31 December 2019, followed up until 28 February 2022 for SARS-CoV-2 first infection and reinfection after 90 days. Cox models were used to compare risk of first infection vs reinfection, adjusting for age, sex, vaccine doses and comorbidities. Results The cohort included 538,516 residents, 121,154 with first SARS-CoV-2 infections and 3,739 reinfections, most in the Omicron BA.1 period. In the pre-Omicron period, three doses of vaccine reduced risk of reinfection by 89% (95% CI: 87–90), prior infection reduced risk by 90% (95% CI: 88–91), while two doses and infection reduced risk by 98% (95% CI: 96–99). In the Omicron BA.1 period, protection estimates were 53% (95% CI: 52–55), 9% (95% CI: 4–14) and 76% (95% CI: 74–77). Before Omicron, protection from reinfection remained above 80% for up to 15 months; with Omicron BA.1, protection decreased from 71% (95% CI: 65–76) at 5 months to 21% (95% CI: 10–30) at 22 months from the first infection. Omicron BA.1 reinfections showed 48% (95% CI: 10–57) lower risk of severe disease than first infections. Conclusions Natural immunity acquired with previous variants showed low protection against Omicron BA.1. Combined vaccination and natural immunity seems to be more protective against reinfection than either alone. Vaccination of people with prior infection reduced the risk of severe disease.Keywords
This publication has 22 references indexed in Scilit:
- Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine doseScience, 2021
- mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infectionScience, 2021
- Cumulative COVID‐19 incidence, mortality and prognosis in cancer survivors: A population‐based study in Reggio Emilia, Northern ItalyInternational Journal of Cancer, 2021
- Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational studyThe Lancet, 2021
- Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care WorkersThe New England Journal of Medicine, 2021
- Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020Eurosurveillance, 2020
- The first case of documented Covid-19 reinfection in IsraelIDCases, 2020
- Temporal profile and determinants of viral shedding and of viral clearance confirmation on nasopharyngeal swabs from SARS-CoV-2-positive subjects: a population-based prospective cohort study in Reggio Emilia, Italy.BMJ Open, 2020
- An interactive web-based dashboard to track COVID-19 in real timeThe Lancet Infectious Diseases, 2020
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987